Home Infusion is growing as new drugs are approved, therapies are added and the population ages. Home infusion is projected to grow by 64% in the next three years and by 2020, the global home infusion market is estimated to reach $27B1. Specialty pharmacy costs are expected to grow 28% year over year2, growing faster than other medical costs.
Infusion therapy is considered a loosely managed segment of the care continuum and payors have historically done little to manage drugs on the medical side. Health plans have historically focused on the pharmacy benefit, but can do more to manage medications paid for under the medical benefit. Other challenges that payors face include managing across the pharmacy/medical benefit, ensuring clinically appropriate use of specialty drugs and monitoring the extremely active pipeline of new drugs including the exponential growth in oncology drugs.
Webinar attendees learned more about:
- Redirection of appropriate drugs to a lower cost site of care
- Oncology infusion directed to the home setting leading to savings potential
- Importance of advanced Clinical Management
- Value of Select Networks and the ability to better understand network’s strengths
 Persistence Market Research (PMR), “Home Infusion Therapy Market Will Reach USD 26.7 billion in 2020.” May 2015.
 Authors: Brian Bruen and Katherine Young. Published by Kaiser Family Foundation, 12/10/14